Q（Question）

Regarding the "person with independence from the company" required as a member of the review and supervisory committee, what degree of independence is required?

A（MHLW answer）

The review and supervisory committee is expected to play a role in ensuring that reviews of promotional materials and monitoring and other supervisory guidance are conducted properly, by providing advice to the supervisory department for promotional information activities without being constrained by the interests of pharmaceutical marketing authorization holders and others. Therefore, it is necessary to carefully determine whether a "person with independence from the company" is someone who can, from the position of an outsider not bound by the interests of pharmaceutical marketing authorization holders, provide firm advice.

So what (meaning): Simply being an external person is insufficient; each candidate must be individually and carefully assessed before appointment to confirm they can give uncompromising advice free from the company's commercial interests.

So why (rationale): An advisor who tempers opinions out of deference to the company's interests renders the committee requirement meaningless and leaves inappropriate materials in circulation.

Commentary — background, application, practical notes

This Q&A on the criteria for a 'person with independence from the company' provides an important conceptual distinction: externality (being outside the company) and independence (being free from interests) are not necessarily the same thing. What the Guidelines require is the latter; the fact of not being an employee alone cannot establish independence. All economic relationships with the pharmaceutical industry, past employment, advisory contracts, and other interests must be mapped out before appointment, and the ability to provide frank advice free from those interests must be confirmed individually.

A typical scenario is evaluating a physician at a university hospital or a professor at a medical school as a committee candidate. If such individuals receive scholarship donations from the company or have served as principal investigators on clinical trials for specific products, independence concerns may arise even though they are external. Likewise, anyone concurrently serving as an advisor to another pharmaceutical company shares industry-wide interests and requires particularly careful assessment.

A common boundary error is failing to distinguish past relationships from current ones. A person who served as a consultant to the company several years ago but has since fully terminated the engagement does not have their independence permanently impaired by that past involvement. However, if the termination is recent, psychological bias may linger, so the length of the interval and the depth of past involvement should be considered holistically. Documenting the appointment assessment process allows the company to demonstrate accountability to regulators.